MDS Pharma Services Adopts SAS(R) Technology for Clinical Trial Data Warehousing and Analysis
16 Giugno 2008 - 2:00PM
PR Newswire (US)
Innovative system gives clients real-time access to data, offers
secure data warehousing and expedites data set conversions for
electronic regulatory submissions KING OF PRUSSIA, PA, June 16
/PRNewswire-FirstCall/ -- MDS Pharma Services, a leading provider
of innovative drug discovery and development solutions, has adopted
the SAS(R) Drug Development tool to provide a centralized,
integrated system for managing, analyzing, reporting and reviewing
clinical research data. SAS Drug Development technology is being
implemented across MDS Pharma Services from the pre-clinical line
of business through Phase IV to integrate worldwide work flows. It
also expedites conversion of data sets into the format established
by the Clinical Data Interchange Standards Consortium (CDISC) for
electronic regulatory submissions. "This powerful tool will
significantly improve our internal operational efficiency and
enhance our ability to provide quality, on-time service to clients
at all phases of their drug development process," said MDS Pharma
Services President David Spaight. "It allows clients to view their
study data even as it is being updated, serves as a secure
repository of legacy clinical trial data, and can convert that data
into standard CDISC format for electronic submission to regulators
as part of a New Drug Application." With the SAS Drug Development
system, MDS Pharma Services can offer medium to large
pharmaceutical industry clients the ability to combine historical
clinical trial data from a variety of sources and studies, convert
it to a common format and analyze it to identify patient safety
issues or new demographic groups with commercial potential. For
biotech clients, this tool will enable the integration of all
available trial datasets and their conversion into a unified data
package for due diligence, subsequent licensing or joint venturing
with a potential commercial development partner. "Collaboration
within the R&D process must include shared visibility to
information," said Jason Burke, worldwide director of Health and
Life Sciences at SAS. "The aggregation and analysis of standardized
data across a compound's lifecycle establishes a foundation for
improving pharmaceutical R&D, and organizations like MDS Pharma
Services that can operationalize these improvements have a distinct
competitive advantage." SAS Drug Development provides a
centralized, integrated system for managing, analyzing, reporting
and reviewing clinical research information. The solution enables
life sciences organizations to get products to market faster by
more effectively assessing the safety and efficacy of research
compounds. The solution also facilitates collaboration across
trials, phases and therapeutic areas. About MDS Pharma Services MDS
Pharma Services is committed to delivering quality service on time.
We offer a full spectrum of resources to meet the drug discovery
and development needs of the pharmaceutical and biotechnology
industries. With numerous facilities strategically located around
the world, we apply advanced scientific and technological expertise
throughout the drug discovery and development process - from lead
optimization, pre-IND research, early clinical research
(bioequivalence, phases I-IIa) and bioanalysis through to global
clinical development (phases IIb-IV), central lab and centralized
cardiac services. For more information, visit our website at
http://www.mdsps.com/. MDS Pharma Services is a business unit of
MDS Inc. (TSX: MDS; NYSE: MDZ), a global life sciences company that
provides market-leading products and services that our customers
need for the development of drugs and diagnosis and treatment of
disease. We are a leading global provider of pharmaceutical
contract research, medical isotopes for molecular imaging,
radiotherapeutics, and analytical instruments. MDS has more than
5,500 highly skilled people in 29 countries. Find out more at
http://www.mdsinc.com/ or by calling 1-888-MDS-7222, 24 hours a
day. DATASOURCE: MDS Pharma Services CONTACT: For Investors: Kim
Lee, (416) 213-4721, ; For Media: Charlene McGrady, (610) 239-7900
ext. 231,
Copyright